Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors

PIK3R1 (p85 alpha regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1 (R348*) and a nearby mutation PIK3R1(L370FS), in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK and JNK inhibitors in vitro and in vivo. Consistent with the response to inhibitors, P1K3R1(R348*) and PIK3R1(L370fs) unexpectedly increase JNK and ERK phosphorylation. Surprisingly, p850 alpha R348* and L370fs localize to the nucleus where the mutants provide a scaffold for multiple JNK pathway components facilitating nuclear JNK pathway activation. Our findings uncover an unexpected neomorphic role for PIK3R1(R348*) and neighboring truncation mutations in cellular signaling, providing a rationale for therapeutic targeting of these mutant tumors.